FDA has granted IDE approval for the STROKE-REWIRE pivotal trial evaluating NeuWire Medical's neurostimulation device for chronic ischemic stroke recovery.
|Poll|August 19, 2015
A 5-year-old with a Hand Burn
Author(s)ReelDx
The mother reports the child spilled hot liquid while removing a cup from the microwave. Does the injury match the claim?
Advertisement
A 5 y/o boy is seen for a hand burn, 9 days post-injury. He was treated in the ED after scalding water spilled on the back of his hand. Silver sulfadiazine was prescribed. Initial blister burst within 1 day of burn. Pain now managable.
Advertisement
Related to this article
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
EASD 2026: Oral semaglutide users lost 4.1% of body weight 3 months after switching from injections in an observational study without a comparator group.
Real-world phase 4 data show fezolinetant eases menopausal hot flashes and improves sleep, cutting nighttime awakenings by 2.6 by week 12.
September FDA news included updates in CKD and type 1 diabetes, major depressive disorder, insulin pump technology, alopecia areata, and more.
EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight difference vs placebo; separate data found less organ fat in type 2 diabetes.
The FDA accepted Bayer's sNDA and granted Priority Review to elinzanetant for vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.
Advertisement
Advertisement
Trending on Patient Care Online
1
9 Drugs Approved for Primary Care: Q3 2026
2
Immunizing Against Pain and Fear: Rethinking the Vaccination Experience
3
Switch to Oral Semaglutide Linked to 4.1% Weight Loss at 3 Months in New Study
4
HIV Testing Before and During PrEP: Getting It Right
5